新药资讯

Company: Sanofi-aventis

Approval Status: Approved on 3/2/2020

Specific treatment: Multiple myloma

Company: AstraZeneca Pharmaceuticals

Approval Status: Approved on 4/10/2020

Specific treatment: Neurofibromatosis type 1

Company: Seattle Genetics

Approval Status: Approved on 4/17/2020

Specific treatment: Metastatic HER2-positive breast cancer

Company: Incyte Corporation

Approval Status: Approved on 4/17/2020

Specific treatment: Cholangiocarcinoma

Company: Immunomedics

Approval Status: Approved on 4/22/2020

Specific treatment: Metastatic triple-negative breast cancer

Company: Novartis Pharmaceuticals

Approval Status: Approved on 5/6/2020

Specific treatment: Non small cell lung cancer

RETEVMO(selpercatinib)

Company: Eli Lilly

Approval Status: Approved on 5/8/2020

Specific treatment: Lung and thyroid cancers